Afuco™ Anti-human Clec2d Adcc Theraputic Antibody, Adcc Enhanced

Country: United States
Founded Year: 2005
Contact: Jerry Carter

Anti-CLEC2D ADCC Enhanced Antibody is an ADCC enhanced antibody produced by our Afuco™ platform. This is a monoclonal antibody that is capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies and to cells that express such antibodies. Antibodies have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis.

https://www.creativebiolabs.net/Anti-CLEC2D-ADCC-Enhanced-Antibody-20469.htm